SAB Biotherapeutics's total assets for Q3 2025 were $183.45M, an increase of 508.87% from the previous quarter. SABS total liabilities were $18.37M for the fiscal quarter, a 1.44% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.